Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 180

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: The empirical basis for U.S. clinical practice

Krystal, Andrew D. · 2009 · Sleep Medicine Reviews

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.smrv.2008.08.001

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 100

  1. Walsh, 2004, Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine, Sleep, 27, 14441, 10.1093/sleep/27.8.1441 · DOI
  2. Walsh, 1998, Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia, Hum Psychopharmacol, 13, 191, 10.1002/(SICI)1099-1077(199804)13:3<191::AID-HUP972>3.0.CO;2-X · doi:10.1002/(sici)1099-1077(199804)13:3<191::aid-hup972>3.0.co;2-x
  3. Krystal, 2004, The changing perspective of chronic insomnia management, J Clin Psychiatry, 65, 20
  4. Hohagen, 1994, Prevalence of insomnia in elderly general practice attenders and the current treatment modalities, Acta Psychiatr Scand, 90, 102, 10.1111/j.1600-0447.1994.tb01563.x · DOI
  5. Hohagen, 1993, Prevalence and treatment of insomnia in general practice. A longitudinal study, Eur Arch Psychiatry Clin Neurosci, 242, 329, 10.1007/BF02190245 · DOI · Paper page
  6. Locniskar, 1990, Oxidative versus conjugative biotransformation of temazepam, Biopharm Drug Dispos, 11, 499, 10.1002/bdd.2510110604 · doi:10.1002/bdd.2510110604
  7. Greenblatt, 1989, Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Flurazepam, temazepam, and triazolam, Arch Gen Psychiatry, 46, 326, 10.1001/archpsyc.1989.01810040032006 · DOI
  8. Yamazaki, 2007, Different effects of light food on pharmacokinetics and pharmacodynamics of three benzodiazepines, quazepam, nitrazepam and diazepam, J Clin Pharm Ther, 32, 31, 10.1111/j.1365-2710.2007.00795.x · doi:10.1111/j.1365-2710.2007.00795.x
  9. Miura, 2004, In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions, Xenobiotica, 34, 1001, 10.1080/02772240400015214 · doi:10.1080/02772240400015214
  10. Greenblatt, 2005, Clonazepam pharmacokinetics: comparison of subcutaneous microsphere injection with multiple-dose oral administration, J Clin Pharmacol, 45, 1288, 10.1177/0091270005280861 · DOI
  11. Crevoisier, 2003, Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers, Eur Neurol, 49, 173, 10.1159/000069089 · DOI
  12. Nims, 1997, In vivo induction and in vitro inhibition of hepatic cytochrome P450 activity by the benzodiazepine anticonvulsants clonazepam and diazepam, Drug Metab Dispos, 25, 750
  13. Fukasawa, 2007, Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines, J Clin Pharm Ther, 32, 333, 10.1111/j.1365-2710.2007.00829.x · DOI
  14. Erdman, 2007, Absence of food effect on the extent of alprazolam absorption from an orally disintegrating tablet, Pharmacotherapy, 27, 1120, 10.1592/phco.27.8.1120 · doi:10.1592/phco.27.8.1120
  15. Greenblatt, 1989, Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition, Pharmacology, 38, 327, 10.1159/000138553 · DOI
  16. Gustavson, 1990, The clinical pharmacokinetics of single doses of estazolam, Am J Med, 88, 2S, 10.1016/0002-9343(90)90278-L · DOI
  17. Greenblatt, 2006, Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo, J Clin Pharmacol, 46, 1469, 10.1177/0091270006293303 · DOI
  18. Pichard, 1995, Oxidative metabolism of zolpidem by human liver cytochrome P450S, Drug Metab Dispos, 23, 1253, 10.1016/S0090-9556(25)06824-2 · DOI
  19. Greenblatt, 1998, Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo, Clin Pharmacol Ther, 64, 553, 10.1016/S0009-9236(98)90139-4 · DOI
  20. Lake, 2002, Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase, Xenobiotica, 32, 835, 10.1080/00498250210158915 · DOI
  21. Fernandez, 1993, Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers, Drug Metab Dispos, 21, 1125, 10.1016/S0090-9556(25)08209-1 · DOI
  22. Ziegler, 1978, Contribution to the pharmacokinetics of amitriptyline, J Clin Pharmacol, 18, 462, 10.1002/j.1552-4604.1978.tb01572.x · doi:10.1002/j.1552-4604.1978.tb01572.x
  23. Richelson, 1984, Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro, J Pharmacol Exp Ther, 230, 94, 10.1016/S0022-3565(25)21446-X · DOI · Paper page
  24. Venkatakrishnan, 1998, Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4, J Clin Pharmacol, 38, 112, 10.1002/j.1552-4604.1998.tb04399.x · DOI
  25. Ghahramani, 1997, Cytochromes P450 mediating the N-demethylation of amitriptyline, Br J Clin Pharmacol, 43, 137, 10.1046/j.1365-2125.1997.05382.x · DOI
  26. Karim, 2006, Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia, J Clin Pharmacol, 46, 140, 10.1177/0091270005283461 · DOI
  27. Greenblatt, 2007, Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2, J Clin Pharmacol, 47, 485, 10.1177/0091270006298602 · DOI
  28. Kirchheiner, 2002, Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers, Pharmacogenetics, 12, 571, 10.1097/00008571-200210000-00010 · doi:10.1097/00008571-200210000-00010
  29. Virtanen, 1980, Single dose pharmacokinetics of doxepin in healthy volunteers, Acta Pharmacol Toxicol (Copenh), 47, 371, 10.1111/j.1600-0773.1980.tb01575.x · DOI
  30. Miller, 1988, Kinetics, brain uptake, and receptor binding characteristics of flurazepam and its metabolites, Psychopharmacology (Berl), 94, 386, 10.1007/BF00174694 · DOI
  31. Mendelson, 2007, Combining pharmacologic and nonpharmacologic therapies for insomnia, J Clin Psychiatry, 68, 19
  32. Greenblatt, 1979, Lorazepam kinetics in the elderly, Clin Pharmacol Ther, 26, 103, 10.1002/cpt1979261103 · DOI
  33. Rotzinger, 1998, Human CYP2D6 and metabolism of m-chlorophenylpiperazine, Biol Psychiatry, 44, 1185, 10.1016/S0006-3223(97)00483-6 · doi:10.1016/s0006-3223(97)00483-6
  34. Banks, 1988, Mediation of serotonin-induced analgesia by the 5HT2 receptor in the pentobarbital anesthetized mouse model, Brain Res Bull, 21, 887, 10.1016/0361-9230(88)90022-6 · doi:10.1016/0361-9230(88)90022-6
  35. Greenblatt, 1987, Trazodone kinetics: effect of age, gender, and obesity, Clin Pharmacol Ther, 42, 193, 10.1038/clpt.1987.132 · DOI
  36. Ishida, 1995, Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine, Int Clin Psychopharmacol, 10, 143, 10.1097/00004850-199510030-00002 · DOI
  37. Rotzinger, 1999, Metabolism of some “second”- and “fourth”-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine, Cell Mol Neurobiol, 19, 427, 10.1023/A:1006953923305 · doi:10.1023/a:1006953923305
  38. Nilsen, 1992, Single dose pharmacokinetics of trazodone in healthy subjects, Pharmacol Toxicol, 71, 150, 10.1111/j.1600-0773.1992.tb00535.x · doi:10.1111/j.1600-0773.1992.tb00535.x
  39. Cohen, 1997, Pharmacokinetics of mirtazapine from orally administered tablets: influence of a high-fat meal, Eur J Drug Metab Pharmacokinet, 22, 103, 10.1007/BF03189792 · DOI
  40. Bookstaff, 1996, Effects of doxylamine succinate on thyroid hormone balance and enzyme induction in mice, Toxicol Appl Pharmacol, 141, 584, 10.1006/taap.1996.0325 · doi:10.1006/taap.1996.0325
  41. Toothaker, 2000, Absence of pharmacokinetic interaction between orally co-administered naproxen sodium and diphenhydramine hydrochloride, Biopharm Drug Dispos, 21, 229, 10.1002/bdd.234 · doi:10.1002/bdd.234
  42. Akutsu, 2007, Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation, Drug Metab Dispos, 35, 72, 10.1124/dmd.106.012088 · doi:10.1124/dmd.106.012088
  43. Luna, 1989, Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives, J Clin Pharmacol, 29, 257, 10.1002/j.1552-4604.1989.tb03323.x · doi:10.1002/j.1552-4604.1989.tb03323.x
  44. Schotte, 1996, Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding, Psychopharmacology, 124, 57, 10.1007/BF02245606 · DOI · Paper page
  45. Sekine, 1999, Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions, Eur J Clin Pharmacol, 55, 583, 10.1007/s002280050676 · DOI
  46. Bymaster, 1996, Radioreceptor binding profile of the atypical antipsychotic olanzapine, Neuropsychopharmacology, 14, 87, 10.1016/0893-133X(94)00129-N · DOI · Paper page
  47. He, 1995, A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors, Int Clin Psychopharmacol, 10, 19, 10.1097/00004850-199503000-00003 · DOI
  48. Beasley, 1996, Olanzapine versus placebo and haloperidol: acute phase results of the north American double-blind olanzapine trial, Neuropsychopharmacology, 14, 111, 10.1016/0893-133X(95)00069-P · DOI · Paper page
  49. Markowitz, 2006, Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers, J Clin Pharmacol, 46, 164, 10.1177/0091270005283839 · DOI
  50. Hajak, 1994, Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo, Int Clin Psychopharmacol, 9, 251, 10.1097/00004850-199400940-00004 · DOI
  51. Drake, 2000, Dose–response effects of zaleplon as compared with triazolam (0.25mg) and placebo in chronic primary insomnia, Hum Psychopharmacol, 15, 595, 10.1002/hup.216 · DOI
  52. Fabre, 1978, Multi-clinic double-blind comparison of triazolam (Halcion) and placebo administered for 14 consecutive nights in outpatients with insomnia, J Clin Psychiatry, 39, 679
  53. Nair, 1990, A dose-range finding study of zopiclone in insomniac patients, Int Clin Psychopharmacol, 5, 1
  54. Scharf, 1990, Estazolam and flurazepam: a multicenter, placebo-controlled comparative study in outpatients with insomnia, J Clin Pharmacol, 30, 461, 10.1002/j.1552-4604.1990.tb03486.x · DOI
  55. Walsh, 1984, A multi-center clinical investigation of estazolam: short-term efficacy, Curr Ther Res, 36, 866
  56. Aden, 1983, Quazepam in the short-term treatment of insomnia in outpatients, J Clin Psychiatry, 44, 454
  57. Fillingim, 1979, Double-blind evaluation of the efficacy and safety of temazepam in outpatients with insomnia, Br J Clin Pharmacol, 8, 73S, 10.1111/j.1365-2125.1979.tb00461.x · DOI
  58. Roehrs, 1983, Dose-related effects of estazolam on sleep of patients with insomnia, J Clin Psychopharmacol, 3, 152, 10.1097/00004714-198306000-00002 · DOI
  59. Scharf, 1994, A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia, J Clin Psychiatry, 55, 192
  60. Elie, 1999, Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group, J Clin Psychiatry, 60, 536, 10.4088/JCP.v60n0806 · DOI · Paper page
  61. Roth, 2006, Zoladult Study Group. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia, Sleep Med, 7, 397, 10.1016/j.sleep.2006.04.008 · DOI
  62. Walsh, 2000, A five week, polysomnographic assessment of zaleplon 10mg for the treatment of primary insomnia, Sleep Med, 1, 41, 10.1016/S1389-9457(99)00006-4 · DOI
  63. Krystal, 2003, Sustained efficacy of eszopiclone over six months of nightly treatment: results of a randomized, double-blind, placebo controlled study in adults with chronic insomnia, Sleep, 26, 793, 10.1093/sleep/26.7.793 · DOI · Paper page
  64. Zammit, 2004, Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia, Curr Med Res Opin, 20, 1979, 10.1185/174234304X15174 · DOI · Paper page
  65. Roth, 2007, Efficacy and safety of doxepin 1mg, 3mg, and 6mg in adults with primary insomnia, Sleep, 30, 1555, 10.1093/sleep/30.11.1555 · DOI · Paper page
  66. Erman, 2006, An efficacy, safety, and dose–response study of ramelteon in patients with chronic primary insomnia, Sleep Med, 7, 17, 10.1016/j.sleep.2005.09.004 · DOI · Paper page
  67. Walsh, 2000, Eight weeks of non-nightly use of zolpidem for primary insomnia, Sleep, 23, 1087, 10.1093/sleep/23.8.1h · DOI · Paper page
  68. Krystal, 2008, Long-term efficacy and safety of zolpidem extended-release 12.5mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study, Sleep, 31, 79, 10.1093/sleep/31.1.79 · DOI · Paper page
  69. Elie, 1990, Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs, Int Clin Psychopharmacol, 5, 39
  70. Reeves, 1977, Comparison of triazolam, flurazepam, and placebo as hypnotics in geriatric patients with insomnia, J Clin Pharmacol, 17, 319, 10.1002/j.1552-4604.1977.tb04611.x · DOI
  71. Piccione, 1980, The efficacy of triazolam and chloral hydrate in geriatric insomniacs, J Int Med Res, 8, 361, 10.1177/030006058000800513 · DOI
  72. Sunshine, 1975, Comparison of the hypnotic activity of triazolam, flurazepam hydrochloride, and placebo, Clin Pharmacol Ther, 17, 573, 10.1002/cpt1975175573 · DOI
  73. Roehrs, 1985, Efficacy of a reduced triazolam dose in elderly insomniacs, Neurobiol Aging, 6, 293, 10.1016/0197-4580(85)90006-5 · DOI
  74. Ancoli-Israel, 1999, Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects, Prim Care Companion J Clin Psychiatry, 1, 114, 10.4088/PCC.v01n0404 · DOI
  75. Hedner, 2000, Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group, Int J Geriatr Psychiatry, 15, 704, 10.1002/1099-1166(200008)15:8<704::AID-GPS183>3.3.CO;2-J · doi:10.1002/1099-1166(200008)15:8<704::aid-gps183>3.3.co;2-j
  76. Scharf, 2005, A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia, Sleep, 28, 720, 10.1093/sleep/28.6.720 · DOI
  77. McCall, 2006, A polysomnography study of eszopiclone in elderly patients with insomnia, Curr Med Res Opin, 22, 1633, 10.1185/030079906X112741 · DOI
  78. Lydiard, 2006, Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial, J Clin Sleep Med, 2, 309, 10.5664/jcsm.26591 · DOI
  79. Roth, 2007, A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia, Curr Med Res Opin, 23, 1005, 10.1185/030079907X178874 · DOI
  80. Roth, 2006, Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia, Sleep Med, 7, 312, 10.1016/j.sleep.2006.01.003 · DOI · Paper page
  81. Morgan, 1990, Hypnotics in the elderly: what cause for concern?, Drugs, 40, 688, 10.2165/00003495-199040050-00004 · DOI
  82. Asplund, 2000, Sleep and hypnotic use in relation to perceived somatic and mental health among the elderly, Arch Gerontol Geraitr, 31, 199, 10.1016/S0167-4943(00)00075-3 · DOI
  83. Ohayon, 1996, The elderly, sleep habits and use of psychotropic drugs by the French population, Encephale, 5, 337
  84. Morgan, 1988, Prevalence, frequency and duration of hypnotic use among elderly living at home, Br Med J, 296, 601, 10.1136/bmj.296.6622.601 · DOI · Paper page
  85. Hayes, 2007, Polypharmacy and the geriatric patient, Clin Geriatr Med, 23, 371, 10.1016/j.cger.2007.01.002 · DOI
  86. Cook, 1983, Hypnotic accumulation and hangover in elderly inpatients: a controlled double-blind study of temazepam and nitrazepam, Br Med J (Clin Res Ed), 286, 100, 10.1136/bmj.286.6359.100 · DOI
  87. Mindell, 2006, Pharmacologic management of insomnia in children and adolescents: consensus statement, Pediatrics, 117, e1223, 10.1542/peds.2005-1693 · DOI · Paper page
  88. National Institutes of Health, 1984, Consensus conference. Drugs and insomnia. The use of medications to promote sleep, JAMA, 251, 2410, 10.1001/jama.251.18.2410 · DOI
  89. Estivill, 2002, Behavior of insomniacs and implication for their management, Sleep Med Rev, 6, S3, 10.1016/S1087-0792(02)80001-6 · DOI
  90. Perlis, 1997, Self-reported sleep disturbance as a prodromal symptom in recurrent depression, J Affect Disord, 42, 209, 10.1016/S0165-0327(96)01411-5 · DOI · Paper page
  91. Thase, 1999, Antidepressant treatment of the depressed patient with insomnia, J Clin Psychiatry, 60, 28
  92. Reynolds, 1997, Which elderly patients with remitted depression remain well with continued interpersonal psychotherapy after discontinuation of antidepressant medication?, Am J Psychiatry, 154, 958, 10.1176/ajp.154.7.958 · DOI
  93. Nolen, 1993, Hypnotics as concurrent medication in depression. A placebo-controlled, double-blind comparison of flunitrazepam and lormetazepam in patients with major depression, treated with a (tri)cyclic antidepressant, J Affect Disord, 28, 179, 10.1016/0165-0327(93)90103-Q · DOI
  94. Londborg, 2000, Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression, J Affect Disord, 61, 73, 10.1016/S0165-0327(99)00195-0 · DOI · Paper page
  95. Krystal, 2007, Evaluation of eszopiclone discontinuation after co-therapy with fluoxetine for insomnia with co-existing depression, J Clin Sleep Med, 3, 48
  96. Pollack, 2008, Eszopiclone co-administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder, Arch Gen Psychiatry, 65, 551, 10.1001/archpsyc.65.5.551 · DOI · Paper page
  97. Walsh, 1996, Effects of triazolam on sleep, daytime sleepiness, and morning stiffness in patients with rheumatoid arthritis, J Rheumatol, 23, 245
  98. Le Bon, 2003, Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations, J Clin Psychopharmacol, 23, 377, 10.1097/01.jcp.0000085411.08426.d3 · DOI · Paper page
  99. Soares, 2006, Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial, Obstet Gynecol, 108, 1402, 10.1097/01.AOG.0000245449.97365.97 · DOI · Paper page
  100. Lineberger, 2006, Defining insomnia: quantitative criteria for insomnia severity and frequency, Sleep, 29, 479, 10.1093/sleep/29.4.479 · DOI

Cited by

See all 180

Metadata

Authors
Krystal, A. D.
Venue
Sleep Medicine Reviews
Publisher
Elsevier BV
Published
2009-08
Volume
13
Issue
4
Pages
265-274
ISSN
1087-0792 (ISSN-L)
OpenAlex
W2060446359
Cited by
180
References
17
FWCI
16.87
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: The empirical basis for U.S. clinical practice. https://app.cochat.ai/papers/10.1016/j.smrv.2008.08.001
The paper
Krystal, A. D. (2009). A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: The empirical basis for U.S. clinical practice. Sleep Medicine Reviews. https://doi.org/10.1016/j.smrv.2008.08.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.